[go: up one dir, main page]

ES2669585T3 - Micropartículas porosas de silicio para la entrega de fármaco para el ojo - Google Patents

Micropartículas porosas de silicio para la entrega de fármaco para el ojo Download PDF

Info

Publication number
ES2669585T3
ES2669585T3 ES05819498.6T ES05819498T ES2669585T3 ES 2669585 T3 ES2669585 T3 ES 2669585T3 ES 05819498 T ES05819498 T ES 05819498T ES 2669585 T3 ES2669585 T3 ES 2669585T3
Authority
ES
Spain
Prior art keywords
eye
drug delivery
porous silicon
silicon microparticles
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05819498.6T
Other languages
English (en)
Inventor
William Freeman
Michael Sailor
Lingyun Cheng
Frederique Cunin
Emily Anglin
Yang Yang Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2669585T3 publication Critical patent/ES2669585T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un dispositivo para entrega de fármaco, para el uso en la entrega controlada de un fármaco o fármacos particular(es) a una ubicación particular del ojo, donde el dispositivo comprende: partículas porosas de silicio o dióxido de silicio con tamaño de micrones, que tienen poros configurados y dimensionados para recibir por lo menos parcialmente por lo menos un fármaco dentro de ellos; y en el que las partículas son adecuadas para ser entregadas dentro o sobre el ojo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES05819498.6T 2004-10-29 2005-10-31 Micropartículas porosas de silicio para la entrega de fármaco para el ojo Expired - Lifetime ES2669585T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62340904P 2004-10-29 2004-10-29
US623409P 2004-10-29
PCT/US2005/039177 WO2006050221A2 (en) 2004-10-29 2005-10-31 Porous photonic crystals for drug delivery to the eye

Publications (1)

Publication Number Publication Date
ES2669585T3 true ES2669585T3 (es) 2018-05-28

Family

ID=36319719

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05819498.6T Expired - Lifetime ES2669585T3 (es) 2004-10-29 2005-10-31 Micropartículas porosas de silicio para la entrega de fármaco para el ojo

Country Status (5)

Country Link
US (3) US20090208556A1 (es)
EP (2) EP1817003B1 (es)
DK (1) DK1817003T3 (es)
ES (1) ES2669585T3 (es)
WO (1) WO2006050221A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
AU2003208935A1 (en) 2002-02-07 2003-09-02 The Regents Of The University Of California Optically encoded particles
EP1817003B1 (en) 2004-10-29 2018-02-21 The Regents of The University of California Porous silicon microparticles for drug delivery to the eye
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
CA3045436C (en) * 2009-01-29 2025-10-07 Forsight Vision4 Inc Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
EP2427179A4 (en) 2009-05-04 2013-09-11 Psivida Inc POROUS SILICON MEDICATION ELUTING PARTICLES
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
HUE057267T2 (hu) 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
HUE054113T2 (hu) 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
CA2816576C (en) 2010-11-01 2020-06-02 Psivida Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
FR2988721B1 (fr) 2012-03-27 2014-04-04 Centre Nat Rech Scient Nanoparticules de silicium poreux fonctionnalisees et leurs utilisations en therapie photodynamique
WO2014130998A1 (en) * 2013-02-25 2014-08-28 Spinnaker Biosciences, Inc. Surface functionalized porous silicon
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
BR112017009660A2 (pt) 2014-11-10 2017-12-19 Forsight Vision4 Inc dispositivos de administração de fármacos expansíveis e métodos de utilização
CN114533898B (zh) 2015-07-09 2025-07-01 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
JP6912475B2 (ja) 2015-11-20 2021-08-04 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 持続放出性薬物送達機器用の多孔質構造体
JP7093955B2 (ja) 2016-04-14 2022-07-01 スピネカー バイオサイエンシーズ， インコーポレイテッド 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
EP3773730A4 (en) 2018-03-27 2021-12-29 The Regents of The University of California Drug delivery formulations
EP3714879A1 (en) 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904336D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904334D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd Carrier system for preparing herbaceous extracts
CN114948864A (zh) * 2021-02-26 2022-08-30 奈力生医股份有限公司 用于将药剂递送到眼后段的方法和其用途
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
WO2024249553A1 (en) 2023-05-31 2024-12-05 University Of Tartu Molecules targeting infected tissues and methods of use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674743A (en) * 1950-09-21 1954-04-13 Romey A Gaiser Therapeutic, cosmetic, and corrective device
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
RU2055555C1 (ru) * 1992-05-07 1996-03-10 Михаил Ефимович Маргус Устройство для лечения глазных болезней
GB9611437D0 (en) * 1995-08-03 1996-08-07 Secr Defence Biomaterial
GB9808052D0 (en) * 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US6322865B1 (en) 1998-07-13 2001-11-27 Patent Holding Company Hollow plastic article formed by a gas-assisted injection molding system
GB9815819D0 (en) * 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
GB9909996D0 (en) 1999-05-01 1999-06-30 Secr Defence Brit eland The SEE Sharp Kabushiki Kaisha 3-1 OPTICS - PATENTS 09/06/99 22:40:35 PAGE 40 NUMBER: 5747 30 JUNE 1999 cations For Patents retary of State for Defence, The Derivatized porous silicon
CA2368679C (en) 1999-05-01 2010-11-09 Qinetiq Limited Derivatized porous silicon
SE9903958D0 (sv) 1999-11-02 1999-11-02 Boerje Sellergren Porous materials for selective binding or transport of molecular guests
GB0008494D0 (en) * 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
GB2365769A (en) * 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
GB0104383D0 (en) * 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
US20020156274A1 (en) * 2001-03-16 2002-10-24 Terfloth Gerald J. Process for preparing maytansinol
US6815850B2 (en) * 2001-07-10 2004-11-09 International Business Machines Corporation Flux leakage barrier in fluid bearing for disk drive
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US20030060878A1 (en) * 2001-08-31 2003-03-27 Shadduck John H. Intraocular lens system and method for power adjustment
US7482168B2 (en) 2001-09-15 2009-01-27 The Regents Of The University Of California Photoluminescent polymetalloles as chemical sensors
US7042570B2 (en) * 2002-01-25 2006-05-09 The Regents Of The University Of California Porous thin film time-varying reflectivity analysis of samples
AU2003208935A1 (en) * 2002-02-07 2003-09-02 The Regents Of The University Of California Optically encoded particles
JP4448441B2 (ja) * 2002-06-05 2010-04-07 ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 眼科用医薬のデリバリーシステム
US7942989B2 (en) 2002-12-10 2011-05-17 The Regents Of The University Of California Porous silicon-based explosive
WO2004071949A2 (en) * 2003-02-13 2004-08-26 The Regents Of The University Of California Nanostructured casting of organic and bio-polymers in porous silicon templates
US7433811B2 (en) * 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
WO2005034725A2 (en) 2003-08-14 2005-04-21 The Regents Of The University Of California Photonic sensor particles and fabrication methods
GB0324483D0 (en) * 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
GB2409924A (en) * 2004-01-06 2005-07-13 Psimedica Ltd Method of making a silicon-phosphorus composite
ATE469924T1 (de) * 2004-08-03 2010-06-15 Agency Science Tech & Res Polymer mit miteinander verbundenen poren zur arzneistoffzufuhr und verfahren
WO2006044957A2 (en) * 2004-10-19 2006-04-27 The Regents Of The University Of California Porous photonic crystal with light scattering domains and methods of synthesis and use thereof
EP1817003B1 (en) * 2004-10-29 2018-02-21 The Regents of The University of California Porous silicon microparticles for drug delivery to the eye
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US9394369B2 (en) * 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
JP2015003902A (ja) * 2013-05-20 2015-01-08 杏林製薬株式会社 血管新生阻害剤

Also Published As

Publication number Publication date
US20220000768A9 (en) 2022-01-06
EP1817003A2 (en) 2007-08-15
US8945602B2 (en) 2015-02-03
US11241380B2 (en) 2022-02-08
US20130224302A1 (en) 2013-08-29
EP3381446A1 (en) 2018-10-03
EP1817003B1 (en) 2018-02-21
US20090208556A1 (en) 2009-08-20
WO2006050221A2 (en) 2006-05-11
WO2006050221A3 (en) 2007-10-11
US20180055765A1 (en) 2018-03-01
DK1817003T3 (en) 2018-05-22
EP1817003A4 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
ES2669585T3 (es) Micropartículas porosas de silicio para la entrega de fármaco para el ojo
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
PE20060523A1 (es) Formas farmaceuticas orales de opioides con liberacion controlada
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
HUE061300T2 (hu) Gyógyszer szállítórendszerek hidrofób gyógyszerekhez és az azokat tartalmazó készítmények
AR046811A1 (es) Formas de dosificacion oral de ziprasidona de liberacion sostenida
DK1474109T3 (da) Anvendelse af syntetiske uorganiske nanopartikler som bærere af ophthalmiske lægemidler
ATE494885T1 (de) Feste arzneimittelformulierung und vorrichtung zu ihrer aufbewahrung und kontrollierten abgabe
WO2006101815A3 (en) Pharmaceutical compositions comprising polyoxaester and active agents for use with osmotic delivery systems
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CL2007002649A1 (es) Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
EA201001244A1 (ru) Система доставки лекарственного средства со стабилизирующим эффектом
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
CL2010001362A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de la sustancia activa 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato; y su uso para el tratamiento y/o prevencion de enfermedades oncologicas e inmunologicas, entre otras.
SV2008002527A (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato ref. p-sv-80.273/ug
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
AR064104A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol